Review article · 2025 · Open access

CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases

Yuanhao Wu, Luyao Han, Yibin Wang, Mengjiao Gu, Yunuo Wang, Jingyue Gao, Hanjing Huang, Chen Li

Frontiers in Immunology, 16, 1625166 · Published 13 August 2025 · DOI 10.3389/fimmu.2025.1625166

Open PDFView at the publisherCite this paper

In brief

“CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases” is a 2025 review article by Yuanhao Wu and 7 co-authors, published in Frontiers in Immunology. OpenAlex counts 12 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.

Citations
12
Most cited in
2026 (11)
Field-weighted impact
1.10
References
56
Authors
8

Abstract

CAR-T therapy, an innovative immunotherapeutic approach, genetically modifies T cells to express CARs, enabling targeted destruction of specific antigen-expressing cells. Initially developed for oncology, CAR-T therapy has shown significant potential in treating autoimmune diseases. By targeting CD19+ B cells, CAR-T therapy has demonstrated rapid and sustained remission in refractory cases, with studies showing normalized laboratory parameters and reduced disease activity. At the same time, CAR-NK, CAAR-T and CAR-Treg technologies further broaden therapeutic strategies. However, some adverse effects also exist, including CRS, ICANS and so on. Despite these challenges, CAR therapy represents a promising advancement in autoimmune disease treatment, with ongoing research aimed at enhancing efficacy, durability, and safety. Continuous innovation is essential to address limitations and optimize therapeutic outcomes.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Wu, Y., Han, L., Wang, Y., Gu, M., Wang, Y., Gao, J., Huang, H., & Li, C. (2025). CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases. Frontiers in Immunology, 16, 1625166. https://doi.org/10.3389/fimmu.2025.1625166

MLA 9

Wu, Yuanhao, et al. “CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases.” Frontiers in Immunology, vol. 16, 2025, p. 1625166. https://doi.org/10.3389/fimmu.2025.1625166.

Chicago

Wu, Yuanhao, Luyao Han, Yibin Wang, Mengjiao Gu, Yunuo Wang, Jingyue Gao, Hanjing Huang, and Chen Li. 2025. “CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases.” Frontiers in Immunology 16: 1625166. https://doi.org/10.3389/fimmu.2025.1625166.

Harvard

Wu, Y. et al. (2025) ‘CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases’, Frontiers in Immunology, 16, p. 1625166. doi:10.3389/fimmu.2025.1625166.

IEEE

Y. Wu et al., “CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases,” Frontiers in Immunology, vol. 16, p. 1625166, 2025, doi: 10.3389/fimmu.2025.1625166.

BibTeX

@article{wu2025therapy,
  title     = {{CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases}},
  author    = {Wu, Yuanhao and Han, Luyao and Wang, Yibin and Gu, Mengjiao and Wang, Yunuo and Gao, Jingyue and Huang, Hanjing and Li, Chen},
  journal   = {Frontiers in Immunology},
  year      = {2025},
  volume    = {16},
  pages     = {1625166},
  doi       = {10.3389/fimmu.2025.1625166},
  url       = {https://doi.org/10.3389/fimmu.2025.1625166}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › CAR-T cell therapy research

  • CAR T-cell therapy
  • autoimmune disease
  • CD19-targeted CAR-T
  • refractory autoimmune disease
  • CAR-NK cells
  • CAR-Tregs
  • cytokine release syndrome
  • immune effector cell-associated neurotoxicity syndrome

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Wu, Y., Han, L., Wang, Y., Gu, M., Wang, Y., Gao, J., Huang, H., & Li, C. (2025). CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases. Frontiers in Immunology, 16, 1625166. https://doi.org/10.3389/fimmu.2025.1625166

How many times has this paper been cited?

12 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Immunology: sign in and open the PDF from this page.

Who wrote this paper?

Yuanhao Wu, Luyao Han, Yibin Wang, Mengjiao Gu, Yunuo Wang, Jingyue Gao, Hanjing Huang, Chen Li.

What is the DOI of this paper?

10.3389/fimmu.2025.1625166, permanently at https://doi.org/10.3389/fimmu.2025.1625166. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.